Project Grant R01DA062237
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA), under its Drug Use and Addiction Research Programs (CFDA 93.279), awarded $1.765 million to the University of Alabama at Birmingham on April 15, 2026, to investigate the impact of cannabis use on T cell function in HIV central nervous system (CNS) reservoir dynamics and neuropathogenesis. The research initiative, scheduled for completion by January 31, 2031, will evaluate how cannabinoids—specifically tetrahydrocannabinol...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of North Carolina at Chapel Hill a Project Grant totaling $416,351 under the Drug Use and Addiction Research Programs (CFDA 93.279) effective September 1, 2025, through May 31, 2030. This research initiative focuses on circuitry and cell-specific exploration of cannabinoid type 1 receptor (CB1R) positive allosteric modulators (PAMs) as a therapeutic approach to address HIV-1–associated neurocognitive...
- Federal Grant Award Summary The Feinstein Institutes for Medical Research received a $1.2M Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded July 15, 2025, with completion scheduled for March 31, 2030. This award supports research investigating transposable element (TE) expression and gene regulation in the context of HIV-1, antiretroviral therapy (ART), and cannabinoid exposure at the single-cell level. The...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $456,268 to The Children's Hospital of Philadelphia Research Institute on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a two-year research project examining antioxidant and cerebral blood flow profiles in people living with HIV (PWH) who use marijuana. The primary deliverable is a comprehensive neuroimaging and spectroscopy study comparing oxidative stress...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $703,675 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test innovative therapeutic approaches for HIV reservoir inactivation in the central nervous system (CNS). The award, effective August 15, 2025, through May 31, 2030, supports research focused on creating microglia-targeting lipid nanoparticles (LNPs) containing...
- Federal Grant Award Summary Award Details: Drexel University received a $684,123 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded March 15, 2026, with a completion date of December 31, 2030. The award supports a cross-model investigation examining the role of inflammasomes in the neurobehavioral and transcriptomic effects of cocaine exposure and Human Immunodeficiency Virus (HIV) infection, to be conducted at...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Nebraska Medical Center (UNMC) a Project Grant totaling $544,256 under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the role of microglial ferritinophagy in HIV and cocaine-mediated neuroinflammation. The research project, initiated May 15, 2026 and concluding February 28, 2031, addresses the persistent neuroinflammation and cognitive decline experienced by approximately...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Miami a $516,914 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on HIV infection of brain pericytes and the synergistic effects of methamphetamine use. The award, obligated on May 1, 2026, with completion targeted for February 28, 2031, supports a transdisciplinary investigation examining how methamphetamine modulates innate immune dysregulation,...
- Federal Grant Award Summary Drexel University received a $445,636 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective May 15, 2026 through February 28, 2031. The award funds research investigating the neural circuit mechanisms underlying inflexible drug seeking in the context of HIV (Human Immunodeficiency Virus) infection. Specifically, the research addresses the co-occurrence of HIV infection and...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $1,084,701 Project Grant to the University of California, Irvine on July 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support the Data Mining and Functional Validation (DMFV)-SCORCH project through March 31, 2030. This interdisciplinary initiative addresses the intersection of opioid use disorder (OUD) and HIV infection by uncovering multi-scale molecular dysregulations through...
Duke University's Office of Research Administration has been awarded $731,879 under the National Institute on Drug Abuse's Drug Use and Addiction Research Programs (CFDA 93.279) for a project entitled "The Impact of Cannabis Use on the Inflammasome in People with HIV." The award, effective May 1, 2026 through February 28, 2031, supports research investigating how recreational cannabis use affects the NLRP3 inflammasome pathway in people with HIV (PWH) and its relationship to HIV-associated comorbidities, particularly neurocognitive impairment. The research will utilize biospecimens and clinical data from a cohort of neurologically phenotyped HIV-infected individuals who use cannabis and non-users to determine the immunomodulatory effects of cannabinoids on inflammasome activation and related health outcomes. This project addresses a significant gap in understanding how cannabis use—which is highly prevalent among PWH—impacts chronic inflammation and immune dysfunction that contribute to accelerated aging in this population. Preliminary findings from the research team indicate distinct microRNA profiles in cannabis users and suppression of inflammatory responses when monocytes from PWH are exposed to tetrahydrocannabinol (THC), warranting further investigation into the mechanisms and clinical implications of cannabinoid modulation of immune activation in HIV-infected individuals.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $731.9k | 4/29/26 |